GSK PLC Earnings - Q3 2026 Analysis & Highlights
GSK reported Q3 sales growth and continued Specialty momentum, reaffirmed its 2026 guidance, and highlighted increased R&D investment, product launches, and late-stage pipeline expansion.
Key financial results
Q3 sales rose 5% to £8.9 billion at constant exchange rates (CER); gross profit increased 7%, SG&A rose 1%, and R&D increased 22%.
Core operating profit grew 5%, with the margin broadly stable, while core EPS increased 1%; higher interest costs after the Nuvalent acquisition and a higher quarterly tax rate weighed on EPS growth.
Year-to-date cash generation from operations (CGFO) was £1.1 billion ahead of the prior year, and free cash flow was up £1.8 billion; management cited business performance, working capital, the linerixibat out-license, and a ViiV special dividend as contributors.
The quarter included a £0.3 billion Accelerate Growth charge; GSK now expects 2026 charges of up to £1 billion.
Business segment results
Specialty Medicines grew 15%, led by Cabenuva, which rose 35%; Apretude grew 21%, Nucala 18%, and the newly launched Exdensur recorded £27 million in quarterly sales.
Oncology launches and products continued to build: Jideytro generated £3 million after its first launch in non-small cell lung cancer, while Blenrep, Ojjaara, and Jemperli were also highlighted for ongoing or strong growth.
Vaccines declined 2%, with Shingrix China destocking partly offset by US growth; the meningitis portfolio grew 12%, supported by US MenB demand and Penmenvy’s first full back-to-school season.
General Medicines was flat as Trelegy offset declines in the established portfolio; Trelegy grew 8% in the US and 11% internationally.
Segment profit figures were not provided in the call.
Capital allocation
GSK declared a Q3 dividend of £0.17.
Management described the Accelerate Growth program as reallocating resources from support services and parts of the supply chain and manufacturing network toward R&D and late-stage development.
GSK cited its Nuvalent acquisition as a targeted business-development investment and reported net debt to core EBITDA of 1.8 times.
Year-to-date free cash flow included $650 million from the linerixibat out-license and a special dividend associated with a change in ViiV shareholding.
Industry trends and dynamics
GSK described the US adult vaccines market as challenging: it was down about 18% year over year, while Shingrix was down about 14%.
US pharmacy Shingrix inventory was approximately 2.3 million doses, versus 1.7 million a year earlier; management attributed the build partly to a later flu season.
In China, Shingrix demand was about 300,000 injections per month, up 60% from the prior year, while inventory had fallen to 1.4 million doses by August.
The IL-5 class was up 12% year over year; GSK said COPD was supporting Nucala’s contribution to the class, while only 6% of COPD patients were on a biologic and around 70% of severe-asthma patients who could use a biologic were not.
GSK said the global triple-inhaler class was the fastest-growing inhaler class, but the US inhaler market and single-inhaler triple-therapy (SITT) class faced pricing pressure.
Competitive landscape
GSK described Cabenuva as the only long-acting injectable HIV treatment regimen and said more than 75% of US patient switches continued to come from competitors.
Trelegy maintained market leadership in the triple-inhaler class for COPD and asthma.
GSK said TSLP competition was pressuring the IL-5 class, while COPD demand partly offset that pressure; it also cited a 15% US price decline for Nucala alongside 39% volume growth.
Management said prior prescribing experience was the strongest predictor of future Blenrep use; US repeat prescribers accounted for about one-third of sales, and updated NCCN guidelines included DREAMM-7 and DREAMM-8 data for second-line-plus patients.
GSK positioned Jideytro as the first and only ROS-1 TKI designed to target resistance mutations and address CNS activity.
For Hibsago, management described the medicine as the first finite chronic hepatitis B treatment with potential for a functional cure and noted that there was no relevant competition.
Macroeconomic environment
GSK cited foreign-exchange headwinds of 1% on sales and 3% on operating profit in its updated 2026 assumptions.
Management said the US adult vaccine market remained challenging and noted that patients’ Medicare deductibles and co-insurance adjustments affected Trelegy’s US performance.
The company cited US inhaler-class pricing pressure and the forthcoming one-off US impact from Trelegy’s CMS-negotiated price; the negotiated 30-day price was $175, a 73% discount to the 2024 list price.
GSK also referred to Shingrix inventory and shipment timing in China, structural CDC ordering and stock-management challenges there, and some parallel-trade impact in Germany and France.
Growth opportunities and strategies
GSK’s stated priorities were maximizing launches, accelerating R&D, and simplifying the organization to redirect resources toward growth and late-stage development.
Launch progress included Blenrep, Exdensur, and Jideytro; management said Exdensur’s US prescribing and patient starts increased after reimbursement processes advanced, and it expected a change in the sales trend.
GSK received Hibsago approvals in the US and Japan and was pursuing Chinese regulatory discussions; the US, Japan, and China were described as representing around 80% of its potential value.
The late-stage pipeline expanded rapidly: 18 Phase III studies had started, with four more on track to start before year-end, bringing the expected 2026 total to 22.
Pipeline highlights included Jideytro and neladalkib in lung cancer, Ris-Rez across tumor types, Mo-Rez in ovarian and endometrial cancer, Jemperli in rectal cancer, and a Phase III flu-vaccine study enrolling adults aged 65 and over.
GSK said it expected a 2027 Phase IIb food-allergy readout for ozureprubart and aimed to start Phase III in the second half of 2027; management cited about 1.6 million people in the US with clinically relevant food-allergy disease.
The Hengrui collaboration included a PDE3/4 program in early clinical development and 11 other undisclosed targets under active evaluation.
Financial Guidance and Outlook
GSK reaffirmed its 2026 guidance, with sales and core operating profit expected in the upper half of their ranges and core operating margin expected to exceed 31% at constant rates.
Core EPS growth was expected in the lower half of its range; full-year interest was projected at £700 million to £750 million, including about £160 million related to Nuvalent.
GSK expected SG&A to be broadly stable, royalties of around £900 million, and R&D growth significantly ahead of sales for 2026.
The company remained on track for approximately £10 billion of CGFO for the full year at constant rates.
Management said 2027 R&D investment was expected to continue growing ahead of sales, with cost-of-goods efficiencies and the shift toward Specialty intended to support profitable growth.
In Q&A, management indicated that Nuvalent-related interest costs would exceed £300 million next year and that the overall net financial charge could be in the order of £900 million to £1 billion, subject to further guidance at year-end.
